US EditionFrance's Sanofi to acquire biotech firm Vicebio for $1.15 billion
LONDON, UNITED KINGDOM, JUL 23 – Sanofi will add Vicebio’s non-mRNA vaccines targeting RSV and hMPV to its portfolio, with potential milestone payments up to $450 million, advancing combination respiratory vaccine development.
- Sanofi announced on July 22, 2025, that it will acquire UK biotech Vicebio Ltd for $1.15 billion upfront plus up to $450 million in milestones.
- Sanofi pursued this deal to broaden its vaccine portfolio by adding non-mRNA technologies and to strengthen its respiratory vaccine pipeline.
- Vicebio, formed by Medicxi in 2018, develops multivalent vaccines including VXB-241, a bivalent vaccine in phase 1 trials targeting RSV and hMPV respiratory viruses.
- Sanofi will gain access to Vicebio's Molecular Clamp technology, which stabilizes viral proteins for easier, refrigerated vaccine distribution and supports next-generation combination shots.
- The acquisition is expected to close in Q4 2025, expanding Sanofi's vaccine offerings without significantly affecting its 2025 financial guidance and enhancing its respiratory disease prevention efforts.
14 Articles
14 Articles
Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio
Sanofi’s Vicebio acquisition brings technology for developing vaccine combinations for multiple pathogens, such as RSV and hMPV. The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu. The post Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio appeared first on MedCity News.
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy - Sanofi (NASDAQ:SNY)
Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The vaccine candidate complements Sanofi’…
Coverage Details
Bias Distribution
- 92% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
